---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-001869"
form_type: "8-K"
ticker: "BTAI"
cik: "0001720893"
company_name: "BioXcel Therapeutics, Inc."
filed_at: "2025-01-08T23:59:59+00:00"
generated_at: "2026-05-28T06:53:58.099500+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioXcel cuts CEO/CFO/CSO 2025 cash comp, grants stock options at $0.4713

## Summary
- CEO Vimal Mehta's 2025 cash compensation reduced to $706,558; granted options for 660,000 shares at $0.4713.
- CFO Richard Steinhart's cash comp reduced to $289,800; granted options for 270,000 shares.
- CSO Frank Yocca's cash comp reduced to $290,500; granted options for 270,000 shares.
- Options vest in 12 equal monthly installments; full acceleration on termination without cause or change in control.

## SEC filing metadata
- accession: 0001104659-25-001869
- form_type: 8-K
- ticker: BTAI
- cik: 0001720893
- company_name: BioXcel Therapeutics, Inc.
- filed_at: 2025-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720893/000110465925001869/0001104659-25-001869-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720893/000110465925001869/tm252221d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-001869
- JSON: https://secwatch.observer/filing/0001104659-25-001869.json
- Plain text: https://secwatch.observer/filing/0001104659-25-001869.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.